In silico

ICIS Middle Eastern Base Oils and Lubricants Conference: The flagship event for the complete base oils value chain

Retrieved on: 
Thursday, September 21, 2023
In silico, International R&D Academy, Valvoline, Lubricant, ICIS, Growth, European Association for Biometrics, Conference, Royal Purple (lubricant manufacturer), Oil, Video game

This flagship event has grown rapidly over the years and presents a unique opportunity for base oils and lubricants executives to network, share ideas, and discuss important industry topics.

Key Points: 
  • This flagship event has grown rapidly over the years and presents a unique opportunity for base oils and lubricants executives to network, share ideas, and discuss important industry topics.
  • The Middle East Base Oils and Lubricants conference is designed to support this market, understand global trends, and share vital information for the development and growth of sales of base oils and lubricants."
  • "The Middle Eastern Base Oils and Lubricants Conference has become a meeting place for industry leaders, making networking an important part of the conference.
  • To find out more about Middle East Base Oils and Lubricants 2023 and to register for the event, please visit https://events.icis.com/website/8329/

UAE Biotech Insilico Medicine Offers Disease Modeling and Target Identification Course Using AI

Retrieved on: 
Friday, May 12, 2023
Molecular biology, Drug development, Therapy, Drug discovery, COVID-19, Ageing, Biomedical Research, Longevity, Intelligence, Aging Research and Drug Discovery, Doctor of Philosophy, Glioblastoma, Chemistry, Student, Insilico Medicine, Artificial intelligence, AI, Research, Idiopathic pulmonary fibrosis, Education Development Center, Medicine, Medical device, Pharmaceutical industry, Design, In silico

Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that it is releasing a course on Disease Modeling and Target Identification , available for free.

Key Points: 
  • Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that it is releasing a course on Disease Modeling and Target Identification , available for free.
  • Through seven lectures, the course guides participants through the latest insights in disease modeling and target discovery – critical areas in biomedical research that involve using computational and experimental approaches to gain insights into the causes of diseases and identify potential targets for drug development.
  • The course uses case studies to illustrate the practical application of the concepts covered.
  • Insilico has supported young researchers in using its platform before.

AI Drug Discovery Company Insilico Medicine Offers Free Course on Target Identification

Retrieved on: 
Wednesday, May 10, 2023
Molecular biology, Drug development, Therapy, Drug discovery, COVID-19, Ageing, Biomedical Research, Longevity, Intelligence, Aging Research and Drug Discovery, Doctor of Philosophy, Glioblastoma, Chemistry, Student, Insilico Medicine, AI, Research, Idiopathic pulmonary fibrosis, Medicine, Pharmaceutical industry, Design, In silico

New York, May 10, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced today that it is releasing a course on Disease Modeling and Target Identification , available for free.

Key Points: 
  • New York, May 10, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced today that it is releasing a course on Disease Modeling and Target Identification , available for free.
  • The course uses case studies to illustrate the practical application of the concepts covered.
  • “This course aligns with our larger mission to accelerate the discovery and development of new therapeutics by making technological breakthroughs accessible to all scientists, including students, who might be interested in pursuing AI drug discovery,” says Insilico Medicine founder and CEO Alex Zhavoronkov, PhD, who is one of the course instructors.
  • And Insilico has been a supporter of the Youth Longevity Association and annually sponsors young scientists to attend the Aging Research and Drug Discovery conference in Copenhagen, a signature event that Zhavoronkov cofounded.

Head of Insilico Medicine’s Hong Kong R&D Center to Give Keynote on AI Drug Discovery at HKUST Big Data Institute

Retrieved on: 
Thursday, May 4, 2023
Learning, In silico, Pharma, DNA, University, Nature, Therapy, Hepatocellular carcinoma, Acceleration, COVID-19, HKT, Ageing, Cancer, ALS, Intelligence, Chemistry, Research, Gene expression, Fosun International, Doctor of Philosophy, Glioblastoma, Fibrosis, Publication, Biomedicine, Patient, Amyotrophy, Insilico Medicine, Drug discovery, Sanofi, Frontiers Media, Nature (journal), IPF, AlphaFold, Idiopathic pulmonary fibrosis, Medical device, Oncotarget, AI

Hong Kong, May 04, 2023 (GLOBE NEWSWIRE) -- Frank Pun, PhD, Head of the Hong Kong R&D Center of Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven drug discovery company, will give a keynote presentation titled “How AI is Transforming Drug Discoveries” at the Hong Kong University of Science and Technology Big Data Institute Workshop on Big Data and Biomedical & Chemistry Science on May 8, 10am, HKT.

Key Points: 
  • Hong Kong, May 04, 2023 (GLOBE NEWSWIRE) -- Frank Pun, PhD, Head of the Hong Kong R&D Center of Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven drug discovery company, will give a keynote presentation titled “How AI is Transforming Drug Discoveries” at the Hong Kong University of Science and Technology Big Data Institute Workshop on Big Data and Biomedical & Chemistry Science on May 8, 10am, HKT.
  • The Company’s software is trained on aging and focused on diseases with high unmet need, and two of its AI-designed drugs have reached clinical trials.
  • Insilico first proved the concept of an AI drug discovery engine in 2016 – screening 72 million compounds and identifying candidate molecules with anti-cancer properties in a paper published in Oncotarget .
  • Dr. Pun leads a team of application scientists in Hong Kong who are further developing PandaOmics , the AI-enabled biological target discovery engine of Insilico’s end-to-end platform and has published widely in top peer-reviewed journals related to his research in AI drug discovery.

High School Student Researchers Find New Brain Tumor Drug Targets Using AI

Retrieved on: 
Tuesday, May 2, 2023
Spanish National Center for Biotechnology, Pine Crest School, Neuron, Drug development, GBM, Drug discovery, Sevenoaks School, Survival, Ageing, Cancer, National Center for Biotechnology Information, Brain, Research, Gene expression, Biomarker, Cell, Aging Research and Drug Discovery, Doctor of Philosophy, Glioblastoma, Science, Student, GLUD1, Shanghai High School International Division, Patient, Dark Ages, Gene Expression Omnibus, Insilico Medicine, Neuroscience, Biology, Growth, AI, Longevity, Gene, Medicine, CNGA3, Molecular Modeling Database, Mobile phone, Pharmaceutical industry, Medical device, In silico

GBM is the most aggressive and common malignant brain tumor, accounting for 16% of all primary brain tumors.

Key Points: 
  • GBM is the most aggressive and common malignant brain tumor, accounting for 16% of all primary brain tumors.
  • Olsen, a student at Sevenoaks School in Kent, UK, began interning at Insilico Medicine in 2021, after discovering her interest in neurobiology and technology.
  • Ren, a student at Shanghai High School International Division, has an interest in biology and biomarkers and joined them in the summer of 2022.
  • He discovered generative AI drug discovery company Insilico Medicine whose founder and CEO, Alex Zhavoronkov, PhD, connected him with Olsen.

Student Researchers Use UAE-Developed Generative AI Technology to Find New Brain Tumor Drug Targets

Retrieved on: 
Tuesday, May 2, 2023
Spanish National Center for Biotechnology, Pine Crest School, Neuron, Drug development, GBM, Drug discovery, Sevenoaks School, Survival, Ageing, Cancer, National Center for Biotechnology Information, Brain, Research, Gene expression, Biomarker, Cell, Aging Research and Drug Discovery, Doctor of Philosophy, Glioblastoma, Science, Student, GLUD1, Shanghai High School International Division, Patient, Dark Ages, Gene Expression Omnibus, Insilico Medicine, Neuroscience, Artificial intelligence, Biology, Growth, AI, Longevity, Gene, State Farm Research and Development Center, Medicine, CNGA3, Molecular Modeling Database, Mobile phone, Medical device, Pharmaceutical industry, In silico

GBM is the most aggressive and common malignant brain tumor, accounting for 16% of all primary brain tumors.

Key Points: 
  • GBM is the most aggressive and common malignant brain tumor, accounting for 16% of all primary brain tumors.
  • Olsen, a student at Sevenoaks School in Kent, UK, began interning at Insilico Medicine in 2021, after discovering her interest in neurobiology and technology.
  • He discovered generative AI drug discovery company Insilico Medicine whose founder and CEO, Alex Zhavoronkov, PhD, connected him with Olsen.
  • It really kick-started my entire career.”
    “I am truly impressed by the commitment of these young researchers,” says Zhavoronkov.

Insilico Medicine Successfully Discovered Potent, Selective, and Orally Bioavailable Small Molecule Inhibitor of CDK8 Using Generative AI

Retrieved on: 
Monday, April 24, 2023
Medicinal chemistry, Pharma, CDK8, CDK, Deep learning, Clinical trial, Cancer, NK, Research, Doctor of Philosophy, Drug design, Acute myeloid leukemia, Chemistry, AML, Publication, Insilico Medicine, Drug discovery, Biology, R, Family, American Chemical Society, Pharmaceutical industry, In silico

In addition to the published molecule, Insilico scientists are progressing with another AI-generated CDK8 inhibitor with a novel structure.

Key Points: 
  • In addition to the published molecule, Insilico scientists are progressing with another AI-generated CDK8 inhibitor with a novel structure.
  • “We described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016 for the first time.
  • Some of my favorite patents combine generative chemistry and generative biology,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine.
  • “I am excited to see  that with the support of generative AI, we have achieved several industry milestones and advanced the drug candidates discovered by generative AI to the clinical stage.

Insilico Medicine Successfully Discovered Potent, Selective, and Orally Bioavailable Small Molecule Inhibitor of CDK8 Using Generative AI

Retrieved on: 
Wednesday, April 12, 2023
Medicinal chemistry, Pharma, CDK8, CDK, Deep learning, Clinical trial, Cancer, NK, Research, Doctor of Philosophy, Drug design, Acute myeloid leukemia, Chemistry, AML, Publication, Insilico Medicine, Drug discovery, Biology, R, Family, American Chemical Society, Pharmaceutical industry, In silico

New York and Hong Kong, April 12, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it has successfully discovered a potent, selective, and orally bioavailable small molecule inhibitor of CDK8 for the treatment of cancer using a structure-based generative chemistry approach enabled by the Chemistry42 multi-modal generative reinforcement learning platform.

Key Points: 
  • New York and Hong Kong, April 12, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it has successfully discovered a potent, selective, and orally bioavailable small molecule inhibitor of CDK8 for the treatment of cancer using a structure-based generative chemistry approach enabled by the Chemistry42 multi-modal generative reinforcement learning platform.
  • In addition to the published molecule, Insilico scientists are progressing with another AI-generated CDK8 inhibitor with a novel structure.
  • Some of my favorite patents combine generative chemistry and generative biology,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine.
  • “I am excited to see  that with the support of generative AI, we have achieved several industry milestones and advanced the drug candidates discovered by generative AI to the clinical stage.

Insilico Medicine Receives FDA Orphan Drug Designation for Generative AI Discovered and Designed Drug for Idiopathic Pulmonary Fibrosis

Retrieved on: 
Wednesday, February 8, 2023
AI, Food, PCC, Insilico Medicine, Student, Idiopathic pulmonary fibrosis, Intelligence, Idiopathic disease, Patient, Multimedia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Drug discovery, Pharma, Senior, IPF, Chronic lung disease, Pharmaceutical industry, In silico

New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to INS018_055 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Key Points: 
  • New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to INS018_055 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
  • “We are pleased to announce that Insilico has achieved numerous drug discovery milestones and provided new clinical hope using generative AI,” said Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine.
  • “Our commitment to treating patients with idiopathic pulmonary fibrosis is reflected in the FDA’s decision to grant orphan drug designation to INS018_055,” said Sujata Rao M.D., Senior Vice President, Head of Clinical Development at Insilico Medicine.
  • “INS018_055 is a potential first-in-class drug candidate discovered by  Insilico's generative AI platform, Pharma.AI, ” said Feng Ren, Ph.D., Co-CEO and Chief Scientific Officer of Insilico Medicine.

Insilico Medicine Opens Largest AI-Powered Biotechnology Research Center in the Middle East

Retrieved on: 
Wednesday, February 1, 2023
IRENA, International Renewable Energy Agency, AI, Research, International Year of Sustainable Tourism for Development, Biotechnology, Ecosystem, Insilico Medicine, R, Longevity, Government, Abu Dhabi Investment Office, Abu Dhabi Investment Council, Ministry of Investment and International Cooperation, Artificial intelligence, Sustainability, Danto Engineering Development Center, Intelligence, Drug discovery, Clinical trial, Chemistry, Pharma, Ageing, Digital economy, Organization, HQ, Medical device, Management, Pharmaceutical industry, In silico

Abu Dhabi, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine ("Insilico"), a clinical-stage artificial intelligence (AI)-driven drug discovery company, is announcing today the opening of the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the region’s largest AI-powered biotechnology research center.

Key Points: 
  • Abu Dhabi, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine ("Insilico"), a clinical-stage artificial intelligence (AI)-driven drug discovery company, is announcing today the opening of the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the region’s largest AI-powered biotechnology research center.
  • Omar Al Olama, the Minister of State for Artificial Intelligence, Digital Economy and Remote Work Applications, Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico, and Alex Aliper, Ph.D., President of Insilico.
  • “We’re excited about this milestone for Insilico Medicine — particularly given it is taking place during the Year of Sustainability.
  • Now, we would like to extend our global infrastructure to the Middle East,” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine.